Cerebral palsy (CP) is the most common motor function disorder in children, with a prevalence ranging from 2.3 to 3.7 per 1000 children in low- and middle-income countries. CP can result from both congenital and acquired causes. Physiotherapy is a standard treatment for CP; however, its effectiveness is limited as it cannot restore brain damage. The first case of cell therapy for a 2.5-year-old child who experienced cerebral ischemia due to cardiac arrest was conducted in 2013. Since then, cell therapy has been applied in numerous cases of cerebral palsy, showing promising outcomes. Nevertheless, key aspects of this approach, such as indications, cell types, dosage, and administration routes, require further investigation. This chapter analyzes various facets of cell therapy for CP, drawing from both the literature and our own experiences. We present the outcomes of our study using cell therapy in CP patients, and we also address the controversies surrounding this treatment approach and its future prospects.
